In
less-developed countries, inexpensive and well-tolerated antibiotics for
therapy of streptococcal infections are often not available. Scientists have
discovered that trimethoprim may provide an option. Bacteria are not generally
resistant to this agent. In a new publication scientists demonstrated three
pathways for the development of resistance -- meaning that streptococci can
easily become resistant to the antibiotic and pass on this trait quickly.
Trimethoprim
inhibits an enzyme of folic acid metabolism called dihydrofolate reductase,
which plays an important role in bacterial growth. Trimethoprim thus prevents
bacteria from proliferating in the body.
A
new study shows that the antibiotic trimethoprim is a therapeutic option for Streptococcus pyogenes infections in
some geographical regions of the world.
For
further details, see:
R.
Bergmann, M. van der Linden, G. S. Chhatwal, D. P. Nitsche-Schmitz. Factors
That Cause Trimethoprim Resistance in Streptococcus pyogenes. Antimicrobial
Agents and Chemotherapy, 2014; 58 (4): 2281 DOI: 10.1128/AAC.02282-13
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources